Finance

Diverse syndicate stands behind EQRx’s mission with $500M series B round

EQRx is planning to deliver on its promise to provide equivalent or better low-cost drugs ahead of schedule with a $500 million series B, with diverse investor interest reflecting a mission that has only gained support during the pandemic.

The series B round, which comes one year after the company’s launch at last year’s J.P. Morgan